Delving into the Latest Updates on Mesenchymal stem cells(Baylor College of Medicine) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication-

Inactive Indication

Frailty SyndromeRespiratory Distress Syndrome, AcuteSARS-CoV-2 acute respiratory disease

Originator Organization

Baylor College of Medicine

Active Organization-

Inactive Organization

VA Office of Research and Development

Baylor College of Medicine

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Frailty is a health state related to the aging process in which multiple body systems gradually lose their built-in reserves. It is a medical condition of reduced function in older adults which is associated with increased risks of adverse outcomes such as falls, disability, admission to hospital, or need for long-term care. Currently, there is no specific medical treatment of frailty. Mesenchymal stem cells (MSCs) are undifferentiated cells that self-replicated, and some may change into a particular cell type. These cells go to areas of injury due to signals released by injured cells. Upon reaching, the target tissue, MSCs repair injury by releasing growth factors and immune modulators to assist in the body's repair process. This initial study will assess the practicability of using MSCs for age-related frailty and provide information for planning a future full study of MSCs for maximizing Veteran's functional independence.

Start Date31 Jan 2023

Sponsor / Collaborator

VA Office of Research and Development

[+2]

NCT04345601

/ CompletedPhase 1/2IIT

Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced ARDS: A Non-Blinded Randomized, Controlled Study

***At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.***
This is a study for patients who have respiratory infection caused by SARS-CoV-2 that have not gotten better. Because there is no standard treatment for this infection, patients are being asked to volunteer for a gene transfer research study using mesenchymal stem cells (MSCs).
Stem cells are cells that do not yet have a specific function in the body. Mesenchymal stem cells (MSCs) are a type of stem cell that can be grown from bone marrow (the spongy tissue inside of bones). Stem cells can develop into other types of more mature (specific) cells, such as blood and muscle cells.
The purpose of this study is to see if MSCs versus controls can help to treat respiratory infections caused by SARS-CoV-2.

Start Date12 Feb 2021

Sponsor / Collaborator

Baylor College of Medicine

[+2]

NCT02107118

/ WithdrawnPhase 1IIT

H-34570: PHASE I Study: The Use of Autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AdMSC) for the Improvement of Erectile and Cardiac Function in Aging Men

Men who present with erectile dysfunction as defined as an IIEF (International Index of Erectile Function) score less than 21 will be evaluated for risk factors for cardiovascular disease (CVD). This is a single-blind study. Subjects will be randomized in a 2:1 fashion for treatment (ARM 1) versus placebo (ARM 2). Adipose tissue (fat) will be harvested from all patients and stem cells will be cultured. For those patients in the placebo arm the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.

Start Date01 May 2015

Sponsor / Collaborator

Baylor College of Medicine

100 Clinical Results associated with Mesenchymal stem cells(Baylor College of Medicine)

Login to view more data

100 Translational Medicine associated with Mesenchymal stem cells(Baylor College of Medicine)

Login to view more data

100 Patents (Medical) associated with Mesenchymal stem cells(Baylor College of Medicine)

Login to view more data

100 Deals associated with Mesenchymal stem cells(Baylor College of Medicine)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Frailty Syndrome	Phase 2	United States	VA Office of Research and Development	31 Jan 2023
Respiratory Distress Syndrome, Acute	Phase 2	United States	Baylor College of Medicine	12 Feb 2021
SARS-CoV-2 acute respiratory disease	Phase 2	United States	Baylor College of Medicine	12 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04345601 (CTgov)	Phase 1/2	Respiratory Distress Syndrome, Acute \| SARS-CoV-2 acute respiratory disease	28	Mesenchymal Stromal Cells (Safety Run In)	cjqmeqfmjq = kxukyntlsl tdwasqsghg (aoflipkbmk, zxcmsgkrnh - uufblfvedr) View more	-	01 Apr 2024
				Mesenchymal Stromal Cells (Mesenchymal Stromal Cells)	cjqmeqfmjq = xwfiiiypyx tdwasqsghg (aoflipkbmk, vrspigtqpl - befmmbgktn) View more